Neurogen Brain and Spine Institute   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Mumbai India (2008)

Organization Overview

First Clinical Trial
2008
NCT02242071
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

allogeneic adipose derived mesenchymal stem cell (5 trials)

stem cells (8 trials)

Drugs in Phase 1 Trials (1)

bone marrow derived mononuclear cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Brain Injuries (Phase 1)

Brain Injuries, Traumatic (Phase 1)

Cerebral Palsy (Phase 1)

Disease (Phase 1)

Intellectual Disability (Phase 1)

Motor Neuron Disease (Phase 2)

Muscular Dystrophies (Phase 1)

Muscular Dystrophies, Limb-Girdle (Phase 1)

Muscular Dystrophy, Duchenne (Phase 1)

Nervous System Diseases (Phase 1)

Paralysis (Phase 1)

Sclerosis (Phase 2)

Spinal Cord Injuries (Phase 2)

Stroke (Phase 1)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial APIs: 3